Drug survival rates of biologic treatments in patients with psoriasis vulgaris

Brunasso, Alexandra Maria Giovanna; Puntoni, Matteo; Massone, Cesare

doi:10.1111/j.1365-2133.2011.10557.x

Cited by 43 publications

(70 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in contrast to another cohort of 103 patients, with an overall higher withdrawal incidence because of severe AEs (9.21%); the relatively small sample size and shorter follow-up time (39 months) may attribute to this variance. 12 With respect to differences across biologic types, AE rates leading to withdrawal in the study of Gniadecki et al 13 was highest for infliximab (14.6%), as it was in another cohort of 650 Spanish patients (14.3%) 11 and in our own cohort (15%). Otherwise, no differences were seen between the biologics in the number of AEs resulting in withdrawal, which is in agreement with our findings.…”

Section: Discussionmentioning

confidence: 71%

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

Kim

Marinas

Qiang

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 71%

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

Kim

Marinas

Qiang

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…AEs were a less common reason for treatment interruption in our patient sample, and withdrawals due to AEs appeared to involve more patients with concomitant PsA and to occur more frequently among infliximab-treated patients, as confirmed by previous reports. [2][3][4] In conclusion, high drug persistence and responder rates were observed in patients treated with an anti-TNF-a drug in dermatological practice. The overall efficacy and safety of anti-TNF-a drugs and the clinical behaviour of clinicians in different circumstances may influence treatment adherence.…”

Section: Discussionmentioning

confidence: 83%

“…[1][2][3][4][5] Treatment adherence is an indicator of treatment success, depending on multiple factors, including efficacy, tolerability, patients' satisfaction and physician's confidence with the drug use. 6 Clinical trials and registries indicate that the overall efficacy of anti-TNF-a decreases over time leading to a progressive reduction of patients' adherence to treatment, loss of efficacy being the major reason for treatment discontinuation followed by occurrence of adverse events (AEs).…”

mentioning

confidence: 99%

“…6 Clinical trials and registries indicate that the overall efficacy of anti-TNF-a decreases over time leading to a progressive reduction of patients' adherence to treatment, loss of efficacy being the major reason for treatment discontinuation followed by occurrence of adverse events (AEs). [1][2][3][4][5] A history of systemic treatment failures, the presence of comorbidities and the type of anti-TNF-a agent have been indicated to be predictors of poor drug survival in psoriasis, while in PsA high C-reactive protein level, concomitant methotrexate use and poor quality of life have been associated with longer drug survival. 7 The aim of this study was to estimate the long-term survival rate of the first course with anti-TNF-a therapy in a retrospective cohort of patients with psoriasis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

et al. 2013

View full text Add to dashboard Cite

SummaryBackground Adherence is an overall marker of treatment success, and it depends on multiple factors including efficacy and safety. Despite the wide use of tumour necrosis factor (TNF)-a blockers in the treatment of plaque-type psoriasis, few data regarding treatment adherence in routine clinical practice are available. Objectives To estimate the long-term survival rate of anti-TNF-a therapy in a cohort of patients with psoriasis in routine clinical practice; to evaluate the reasons for and predictors of treatment discontinuation. Methods The Outcome and Survival rate Concerning Anti-TNF Routine treatment (OSCAR) study was based on a retrospective analysis to estimate the long-term survival rate of the first anti-TNF-a treatment in patients with psoriasis, from three Italian academic referral centres. Adult patients (n = 650) with plaque psoriasis treated with a first course of adalimumab, etanercept or infliximab for ≥ 3 months were included. Results Global adherence to anti-TNF-a treatments after 28Á9 AE 15Á4 months (867 AE 462 days) of observation was 72Á6%. Etanercept showed a longer survival (mean 51Á4 months, 1565 days; P < 0Á001) compared with infliximab (36Á8 months, 1120 days) and adalimumab (34Á7 months, 1056 days). Treatment discontinuation due to primary and secondary inefficacy was observed in 5Á2% and 14Á5% of patients, respectively, whereas discontinuation due to adverse events was reported in 29 subjects (4Á5%). Independent predictors of treatment withdrawal were female gender [hazards ratio (HR) 1Á3], treatment with adalimumab or infliximab compared with etanercept (HR 2Á7 and 1Á7, respectively), and the concomitant use of traditional systemic treatment, as a rescue therapy, compared with monotherapy (HR 1Á9). Conclusions Overall survival of anti-TNF-a agents in psoriasis is elevated, with drug discontinuation mostly due to inefficacy. Etanercept showed a longer adherence compared with adalimumab and infliximab.

show abstract

“…Three of these studies have only reported on drug survival with TNFIs (Brunasso et al, 2012;Esposito et al, 2013;Gniadecki et al, 2011), while two involved the same Danish national psoriasis biologic safety registry data DERMBIO (Gniadecki et al, 2014;Gniadecki et al, 2011), with the other centres reporting data from either a single or a limited number of centres (Menting et al, 2014;Umezawa et al, 2013;van den Reek et al, 2014c). The…”

Section: Introductionmentioning

confidence: 96%

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Warren

Smith

Yiu

et al. 2015

Journal of Investigative Dermatology

340

354

View full text Add to dashboard Cite

Drug survival reflects a drug's effectiveness, safety, and tolerability. We assessed the drug survival of biologics used to treat psoriasis in a prospective national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register (BADBIR)). The survival rates of the first course of biologics for 3,523 biologic-naive patients with chronic plaque psoriasis were compared using survival analysis techniques and predictors of discontinuation analyzed using a multivariate Cox proportional hazards model. Data for patients on adalimumab (n=1,879), etanercept (n=1,098), infliximab (n=96), and ustekinumab (n=450) were available. The overall survival rate in the first year was 77%, falling to 53% in the third year. Multivariate analysis showed that female gender (hazard ratio (HR) 1.22; 95% confidence interval (CI): 1.09-1.37), being a current smoker (HR 1.19; 95% CI: 1.03-1.38), and a higher baseline dermatology life quality index (HR 1.01; 95% CI: 1.00-1.02) were predictors of discontinuation. Presence of psoriatic arthritis (HR 0.82; 95% CI: 0.71-0.96) was a predictor for drug survival. As compared with adalimumab, patients on etanercept (HR 1.63; 95% CI: 1.45-1.84) or infliximab (HR 1.56; 95% CI: 1.16-2.09) were more likely to discontinue therapy, whereas patients on ustekinumab were more likely to persist (HR 0.48; 95% CI: 0.37-0.62). After accounting for relevant covariates, ustekinumab had the highest first-course drug survival. The results of this study will aid clinical decision making when choosing biologic therapy for psoriasis patients.

show abstract

Drug survival rates of biologic treatments in patients with psoriasis vulgaris

Cited by 43 publications

References 5 publications

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Contact Info

Product

Resources

About